LKPC(SH:600789) Ge Long Hui A P P·2025-08-13 09:31Core Viewpoint - The company, LuKang Pharmaceutical (600789.SH), has received approval from the National Medical Products Administration for its drug, Cefuroxime Axetil Dry Suspension, which has passed the consistency evaluation of generic drug quality and efficacy [1] Group 1: Company Information - LuKang Pharmaceutical has been granted a "Drug Supplement Application Approval Notice" for Cefuroxime Axetil Dry Suspension (Certificate No: 2025B02754) [1] - The drug is a prodrug of Cefuroxime and belongs to the second generation of cephalosporin antibiotics [1] - The mechanism of action of the drug involves inhibiting bacterial cell wall synthesis, preventing bacterial reproduction [1] Group 2: Drug Characteristics - Cefuroxime Axetil exhibits broad-spectrum antibacterial activity against various bacteria, including Streptococcus pyogenes, Streptococcus pneumoniae, Staphylococcus aureus (methicillin-sensitive strains), Haemophilus influenzae, and Neisseria gonorrhoeae [1] - The drug also shows good efficacy against Enterobacteriaceae such as Escherichia coli, Klebsiella pneumoniae, and Proteus species [1]